Literature DB >> 27115819

CNS infection safety signal of RTS,S/AS01 and possible association with rabies vaccine.

Bradford D Gessner1, David C Wraith2, Adam Finn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27115819     DOI： 10.1016/S0140-6736(16)30081-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Authors:  Mehreen S Datoo; Magloire H Natama; Athanase Somé; Ousmane Traoré; Toussaint Rouamba; Duncan Bellamy; Prisca Yameogo; Daniel Valia; Moubarak Tegneri; Florence Ouedraogo; Rachidatou Soma; Seydou Sawadogo; Faizatou Sorgho; Karim Derra; Eli Rouamba; Benedict Orindi; Fernando Ramos Lopez; Amy Flaxman; Federica Cappuccini; Reshma Kailath; Sean Elias; Ekta Mukhopadhyay; Andres Noe; Matthew Cairns; Alison Lawrie; Rachel Roberts; Innocent Valéa; Hermann Sorgho; Nicola Williams; Gregory Glenn; Louis Fries; Jenny Reimer; Katie J Ewer; Umesh Shaligram; Adrian V S Hill; Halidou Tinto
Journal:  Lancet       Date:  2021-05-05       Impact factor: 202.731

2.  Sex-differential non-specific effects of adjuvanted and non-adjuvanted rabies vaccines versus placebo on all-cause mortality in dogs (NERVE-Dog study): a study protocol for a randomized controlled trial with a nested case-control study.

Authors:  Darryn L Knobel; Anne Conan; Felix N Toka; Sintayehu M Arega; Charles Byaruhanga; Eric Ogola; Erick M O Muok; Jan E Crafford; Andrew L Leisewitz; Melvyn Quan; Mary Anna Thrall
Journal:  BMC Vet Res       Date:  2022-10-01       Impact factor: 2.792

3.  Non-specific effects of rabies vaccine on the incidence of common infectious disease episodes: study protocol for a randomized controlled trial.

Authors:  Darryn Knobel; Christianah Ibironke Odita; Anne Conan; Donna Barry; Marshalette Smith-Anthony; Juliet Battice; Shianne England; Bradford D Gessner
Journal:  Trials       Date:  2020-06-16       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.